Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKG:9989)
4.580
-0.010 (-0.22%)
Apr 3, 2025, 4:08 PM HKT
HKG:9989 Revenue
In the year 2024, Shenzhen Hepalink Pharmaceutical Group had annual revenue of 5.26B CNY, down -3.43%. Shenzhen Hepalink Pharmaceutical Group had revenue of 1.19B in the quarter ending December 31, 2024, a decrease of -13.91%.
Revenue
5.26B CNY
Revenue Growth
-3.43%
P/S Ratio
n/a
Revenue / Employee
2.53M CNY
Employees
2,080
Market Cap
16.39B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5.26B | -186.65M | -3.43% |
Dec 31, 2023 | 5.45B | -1.71B | -23.94% |
Jan 1, 2023 | 7.16B | 794.23M | 12.48% |
Jan 1, 2022 | 6.37B | 1.03B | 19.38% |
Dec 31, 2020 | 5.33B | 707.42M | 15.30% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 29.60B |
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 61.89B |
WuXi Biologics | 19.87B |
Innovent Biologics | 10.03B |
Akeso | 2.26B |
Alibaba Health Information Technology | 31.39B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |